ÂÜÀòÂÒÂ×

Stéphane is a seasoned healthcare leader with a strong sense of both strategy and execution in diverse environments. He has experience with large and small teams and is acutely aware of the challenges of a high-potential start-up. He combines a unique expertise in Pharmaceuticals industry as well as in Medical Devices/regenerative medicine, two core markets for Jellagen products. His C-suite and Board experience gives him the ability to articulate shareholder perspective and operational priorities.

Stéphane holds a Master in Management for the prestigious French Business School HEC. Over the last thirty years, Stephane held executive responsibilities at Sanofi (Roussel Uclaf General Manager in Mexico, Australia, France), GSK (French Operations, VP EU Business Development) and BMS (VP Europe and General Manager France). In 2007 Stéphane joined Ipsen as a Member of the Executive Committee, in charge of pre-clinical, clinical, pharmaceutical development, regulatory affairs, business development and legal affairs. In 2011 he then moved to Smith & Nephew as VP Europe and President Advanced Surgical Devices Europe. In 2013 his responsibilities expanded to Japan, Australia, New Zealand and Canada. He has been appointed CEO of Mayoly-Spindler in August 2014.

Stéphane left his position as CEO of French pharma Mayoly-Spindler in 2018 to found and lead AlgoTherapeutix, an R&D company specialized in repurposing medicines for the treatment of complex pain. He is an Investor in a dozen young companies, and a Senior Advisor to Hoalen (textile), Ythera (healthcare) and Pegacsy (oncology). Stéphane has been appointed Non-Executive Director and Chairman of Jellagen Board in April 2018.